At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDX Celldex Therapeutics
Post-Mkt 02-25 18:00:52 EST
30.82
+5.98
+24.07%
盘后30.70
-0.12-0.39%
17:53 EST
High31.00Low25.40Vol3.80M
Open25.55D1 Closing24.84Amplitude22.54%
Mkt Cap2.05BTradable Cap1.64BTotal Shares66.45M
T/O113.17MT/O Rate7.14%Tradable Shares53.21M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)
Reuters  ·  05:02
Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)
Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01
THOMSON REUTERS  ·  05:01
Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01
Celldex Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Dow Jones  ·  01:18
Celldex Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early
Dow Jones  ·  02-25 23:56
Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
TIPRANKS  ·  02-25 23:50
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria
Reuters  ·  02-25 20:03
BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria
Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria
THOMSON REUTERS  ·  02-25 20:01
Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria
Celldex Therapeutics Inc - Topline Data Expected Q4 2026
THOMSON REUTERS  ·  02-25 20:01
Celldex Therapeutics Inc - Topline Data Expected Q4 2026
Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat
Reuters  ·  02-23 21:55
Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat
Celldex to Present Phase 2 Barzolvolimab Data at AAAAI Annual Meeting
Reuters  ·  02-23 21:02
Celldex to Present Phase 2 Barzolvolimab Data at AAAAI Annual Meeting
Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil
Reuters  ·  02-09
Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses
Simply Wall St.  ·  02-04
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
TIPRANKS  ·  01-22
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
Celldex (CLDX) Gets a Buy from Mizuho Securities
TIPRANKS  ·  01-09
Celldex (CLDX) Gets a Buy from Mizuho Securities
Barclays Remains a Sell on Celldex (CLDX)
TIPRANKS  ·  01-09
Barclays Remains a Sell on Celldex (CLDX)
Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy
Reuters  ·  01-08
Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy
Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?
Simply Wall St.  ·  2025-12-22
Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?
Celldex Therapeutics Is Maintained at Underweight by Barclays
Dow Jones  ·  2025-12-18
Celldex Therapeutics Is Maintained at Underweight by Barclays
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?
Simply Wall St.  ·  2025-12-11
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?
BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism
Reuters  ·  2025-12-09
BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism

Introduction

Company Name.
Celldex Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Issue price:
--